Obesity and Its Impact Today on Cardiometabolic Care

Understand the importance of cardiometabolic care for obesity. Discover tips for improving health and wellness.

Abstract

In this comprehensive educational post, I, Dr. Alex Jimenez, share an integrated, first-person journey through modern obesity medicine and metabolic health, grounded in evidence-based research and enriched by clinical experience. I present a multidisciplinary model of care at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where I collaborate with Dr. Maria Guadalupe Cardenas, MD (Internal Medicine; NPI #1164426749; Texas MD License #J2933), our Medical Director and Collaborative Physician with over 40 years of clinical experience. Together, we merge integrative chiropractic care, internal medicine oversight, functional medicine, personal injury rehabilitation, targeted nutrition, and advanced pharmacotherapy to address complex challenges in women’s and men’s health.

I walk readers through detailed, real-world case narratives that illuminate key clinical topics: insulin resistance, visceral adipose tissue, appetite hormone dysregulation (ghrelin, leptin, GLP-1), perimenopause and menopausal hormone therapy (MHT), obstructive sleep apnea (OSA), cardiometabolic risk, sarcopenic obesity, fertility considerations, deprescribing strategies for insulin, and the ethical use of modern anti-obesity medications including semaglutide and tirzepatide. Throughout, I explain physiological underpinnings, decision rationales, and practical protocols, while highlighting how integrative chiropractic care supports nervous system regulation, biomechanics, pain reduction, and movement confidence. This post emphasizes shared decision-making, stigma reduction, monitoring safeguards, and long-term habit formation. It concludes with an extensive hyperlinked reference list using APA-7 style citations, reflecting leading journals and guideline bodies.

My Integrative Philosophy of Care: How Our Multidisciplinary Model Works

I am Dr. Alex Jimenez, and my clinical path spans chiropractic, advanced practice nursing, functional medicine, and injury rehabilitation. My credentials—DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST—reflect my commitment to seeing the whole person and integrating the best of structural, metabolic, and behavioral care.

At Injury Medical Clinic PA, our work is powered by a collaborative structure common to leading integrative and injury care clinics: a chiropractor and a board-certified internist working side by side. Our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD (Internal Medicine), brings unparalleled depth with more than four decades of practice (NPI #1164426749; Texas MD License #J2933). She provides the medical direction essential for safe, evidence-based diagnostics, prescribing, and risk management, while I lead the integrative chiropractic, functional medicine, and rehabilitation components.

• What our multidisciplinary integration looks like:

• • Medical oversight (Dr. Cardenas): diagnostics, labs, imaging, cardiovascular and endocrine risk stratification, medication management, monitoring for adverse events, and inter-specialty coordination.
  • Integrative chiropractic care (Dr. Jimenez): nervous system modulation, spinal and extremity joint optimization, soft-tissue therapies, functional neurology perspectives, and movement biomechanics to reduce pain and enable activity.
  • Functional medicine: root-cause analyses of metabolic, hormonal, inflammatory, and environmental contributors; personalized nutrition; sleep and stress strategies; and targeted supplementation where appropriate.
  • Rehabilitation and personal injury care: structured progressions blending mobility, strength training, posture correction, and reconditioning.
  • Care pathways: obesity medicine, cardiometabolic risk reduction, women’s health (PCOS, perimenopause and MHT), men’s health (hypogonadism, fertility, NAFLD/NASH, sleep apnea), musculoskeletal pain, and neurofunctional optimization.

My patient care voice is rooted in clinical observations I share publicly across dralexjimenez.com and my professional profile: I aim to demystify complex mechanisms and empower people with compassion, clarity, and practical steps.

Why Obesity Is a Complex, Chronic Disease: A Physiological Tour

Modern obesity medicine rejects simplistic “willpower” narratives. It recognizes obesity as an intricate, chronic, relapsing disease driven by hormonal signals, neurochemistry, inflammation, stress, sleep, and environment. To treat it effectively, we must understand the biology and deploy tools that restore physiological balance.

• Key concepts I explain to patients:

• • The “chemical vs. character” distinction: Most overeating is a chemically driven physiology problem—elevated ghrelin, reduced leptin signaling, diminished GLP-1, hyperinsulinemia—rather than a moral failing.
  • Visceral adipose tissue (VAT): Highly inflammatory, endocrine-active fat that secretes adipokines disrupting insulin sensitivity, blood pressure, lipid metabolism, and vascular health.
  • Insulin resistance and hyperinsulinemia: As cells resist insulin’s signal, the pancreas compensates by secreting more insulin, driving fat storage, hunger, and cardiometabolic risk.
  • Stress and sleep: Chronic stress amplifies cortisol, feeding VAT accumulation and appetite; sleep deprivation further destabilizes appetite hormones and blood pressure.
  • Neurohormonal “food noise”: Dysregulated reward and satiety pathways can produce intrusive, persistent hunger cues; addressing them medically is often necessary.

This framework guides our clinical decision-making, from nutrition strategy and chiropractic-supported movement to advanced pharmacotherapy and collaboration with sleep medicine, endocrinology, cardiology, and behavioral health.

Our Integrative Care Map: Stepwise, Patient-Centered, Evidence-Based

I employ a methodical, safety-first approach. We build foundations, then layer treatments strategically, always tracking objective data and personal goals.

• Core pillars of our model:
  • Baseline diagnostics and risk assessment:

• • • Anthropometrics: waist circumference as a proxy for VAT.
    • Labs: fasting glucose and insulin, HOMA-IR, HbA1c, lipids, liver enzymes, thyroid panel, renal function, inflammatory markers as appropriate.
    • Sleep evaluation: OSA screening and formal sleep studies when indicated.
    • Body composition: DEXA or bioimpedance trends to differentiate fat vs. muscle changes.

• • Lifestyle and chiropractic integration:

• • • Nutritional counseling by registered dietitians focused on insulin resistance and muscle preservation: whole-foods emphasis, protein pacing, fiber-rich plants, glycemic management.
    • Movement: progressive, realistic activity goals; resistance training to protect lean mass; chiropractic adjustments and soft-tissue therapies to reduce pain and facilitate motion.
    • Stress and sleep: structured meditation options, sleep hygiene protocols, and nervous-system regulation via chiropractic care.

• • Medical therapeutics and safeguards:

• • • Treat hypertension, lipids, and emergent risks first.
    • Consider MHT for perimenopausal symptom control when criteria are met.
    • Incretin-based therapies (GLP-1, GIP/GLP-1) to quiet food noise, improve glycemia, and reduce weight with cardiovascular benefits.
    • Combination pharmacotherapy when biological “fight back” emerges.
    • Monitor for adverse events; deprescribe insulin when appropriate.

• • Shared decision-making:

• • • Patients define success (heart health, fertility, stamina, pain relief); weight loss becomes a means to meaningful life outcomes.

This living map adapts as each person’s biology and circumstances evolve, forging sustainable change and resilience.

Case Narrative: George’s Metabolic Turnaround and Fertility Success in Men’s Health

George, a 35-year-old project manager, arrived burdened by elevated blood pressure, low sperm count, intermittent erectile dysfunction, anxiety, poor sleep, and persistent hunger. He felt shame about appetite control—precisely the self-blame I work to reframe.

• Initial insights:

• • Elevated waist circumference indicated high VAT.
  • Fasting insulin and glucose were elevated; HOMA-IR was 3.1, consistent with insulin resistance.
  • Missing labs (HbA1c, thyroid, liver panel) were ordered to complete the picture.
  • His stress and sleep dysregulation fueled cortisol and sympathetic dominance, worsening appetite and musculoskeletal tension.

• Physiological explanation I share:

• • Excess adipose tissue upregulates aromatase, converting testosterone to estrogen, lowering androgen levels vital for mood, muscle, and fertility.
  • Hyperinsulinemia and leptin resistance blunt satiety; ghrelin and diminished GLP-1 amplify hunger; low-grade inflammation disrupts metabolism.

• The initial plan:

• • Complete labs and stabilize blood pressure.
  • Refer to a dietitian for practical, context-aware nutrition strategy at work and home.
  • Sleep medicine referral for suspected OSA.
  • Consider pharmacotherapy for obesity; set realistic movement goals and short meditations.

• Four-week follow-up:

• • HbA1c was 5.9% (prediabetes); thyroid and liver panels normal; sleep study scheduled; dietitian engagement ongoing.
  • Weight had risen slightly—an opportunity to normalize variability, identify barriers (feeling “silly” about meditation; low energy), and adjust.

• Updated interventions:

• • Titrate blood pressure meds.
  • Plan for bupropion-naltrexone for mood and cravings, starting after sleep study to avoid interference.
  • Make meditation accessible: short, guided sessions in the car.
  • Reframe activity as “move more” and leverage chiropractic care to reduce tension and support biomechanics.

• Four months later:

• • OSA confirmed; CPAP use restored sleep architecture and energy.
  • Mood improved; lunch walks began; weight decreased.
  • Persistent hunger led us to add semaglutide (GLP-1 agonist), starting at 0.25 mg weekly, tapering off naltrexone while continuing bupropion.
  • Monitor body composition and add resistance training with adequate protein to protect lean mass.

• One-year results:

• • Blood pressure controlled; fasting markers normalized; HOMA-IR improved to 1.64; HbA1c normalized.
  • Waist circumference down, reflecting lower VAT.
  • Semaglutide stabilized at an individualized 1.7 mg maintenance dose—not maximal, but right for him.
  • Most meaningful outcome: improved fertility—his spouse expecting a baby—plus strong daytime energy, resilient habits, and stress management.

• Why this worked:

• • Treating sleep apnea and blood pressure removed physiologic stressors.
  • Incretin therapy quieted food noise and enabled consistent nutrition.
  • Chiropractic care reduced musculoskeletal tension, facilitating movement and autonomic balance.
  • Goals focused on heart health, family building, and vitality—over numbers on a scale—anchoring motivation.

Case Narrative: Lynn’s Perimenopause, MHT, and Metabolic Reset in Women’s Health

Lynn, a 42-year-old event planner, presented with fatigue, brain fog, mood swings, hot flashes, poor sleep, elevated blood pressure, weight gain, and emerging metabolic dysfunction—while grieving a recent loss and navigating fragmented primary care. She felt dismissed when she raised perimenopause concerns, a common experience among women I advocate fiercely to correct.

• Baseline profile:

• • Waist circumference above 35 inches indicated high VAT-associated cardiometabolic risk.
  • A1c and lipids suggested early metabolic disruption; slight liver enzyme elevations flagged NAFLD risk; thyroid and kidneys were normal.

• My integrative chiropractic view:

• • Fluctuating estrogen affects collagen and joint comfort; combined stress and deconditioning create postural strain and stiffness.
  • Gentle adjustments, soft-tissue work, and corrective exercises can ease pain and improve nervous-system function, reducing allostatic load while we treat root physiology.

• Shared goals:

• • Alleviate perimenopausal symptoms (“feel like herself again”).
  • Normalize blood pressure.
  • Halt weight gain and reduce VAT.

• Why start with MHT:

• • Lynn fits the optimal window: under 60 and within 10 years of last menses, where MHT benefits often outweigh risks (Manson et al., 2013).
  • Transdermal estradiol and oral bioidentical progesterone protect the endometrium, lower VTE risk vs. oral estrogen, and stabilize symptom control (Canonico et al., 2007).
  • Methodical introduction avoids confounding adverse-event attribution; we build one layer at a time.

• Foundations:

• • Dietitian-led nutrition for glycemic stability and muscle preservation.
  • Therapist referral for grief processing; stress strategies.
  • Home blood pressure monitoring; hydration and sleep hygiene.
  • Chiropractic care for pain relief and autonomic support to improve energy and mood.

• Six-week follow-up:

• • Dramatic improvements in sleep, hot flashes, brain fog, and energy.
  • Walking routine established; blood pressure trending down; small weight loss.
  • Ready to layer advanced metabolic support: we introduced tirzepatide at 2.5 mg weekly (dual GIP/GLP-1 agonist), expanding satiety signals and glycemic benefits beyond GLP-1 alone (Frias et al., 2021).

• Safeguards:

• • Monitor body composition at baseline and 3 months to ensure fat loss with muscle preservation.
  • Protein pacing and resistance training are non-negotiable to counter sarcopenia risk and maintain resting metabolic rate.
  • GI side effects education; red-flag symptom guidance for rare but serious events (e.g., severe abdominal pain, intractable vomiting).

• Three-year trajectory:

• • Sustained medication tolerance (MHT and tirzepatide maintenance), excellent body composition preservation, thriving movement habits after pivoting away from an unenjoyable class to a favorite cardio-strength format.
  • Periodic dietitian tune-ups; resumed therapy during family illness stress flare.
  • Weight stabilization over small regain—normalized as part of long-term physiology—paired with strong function and confidence.

• Why this worked:

• • MHT stabilized perimenopausal volatility driving fatigue and cognition.
  • Dual-incretin therapy enhanced satiety and glucose control, complementing lifestyle.
  • Chiropractic care reduced pain and improved nervous-system tone, enabling consistent activity.
  • Continuity of compassionate, validating care healed mistrust and fueled adherence.

Case Narrative: Amit’s High-Risk Cardiometabolic Profile and Insulin Deprescribing Strategy

Amit, 57, exemplifies advanced metabolic disease: long-standing type 2 diabetes on basal/bolus insulin, prior myocardial infarction, PAD (stage IIa), OSA, hypertension, hyperlipidemia, MASLD (stage 2), low testosterone, erectile dysfunction, high waist circumference (51.25 inches), and profound sarcopenic obesity (body fat 56.7%, skeletal muscle in the 4th percentile). His hunger was near-constant; satiety was weak; physical activity was limited by claudication.

• Why his baseline was so dangerous:

• • Atherogenic dyslipidemia (high triglycerides, low HDL) elevates cardiovascular risk.
  • Insulin therapy “shouts” at insulin-resistant tissues; it lowers glucose acutely but worsens fat storage and inflammation over time.
  • Sarcopenic obesity combines frailty risk with cardiometabolic burden, raising mortality (Stenholm et al., 2008).

• Our aggressive but stepwise plan:
  • Nutrition: Mediterranean-style emphasis matched cultural preferences; protein pacing to target 90–100 g daily; minimize refined carbohydrates and alcohol.
  • Physical therapy: supervised walking into claudication (rest-then-repeat for collateral vessel building), stationary bike, progressive strength training.
  • Pharmacology:

• • • Initiate semaglutide with cardiovascular risk reduction indication per SELECT trial findings (Lincoff et al., 2023), titrating toward 2.4 mg.
    • Deprescribe insulin strategically—often stopping bolus and sometimes basal at GLP-1 initiation—with continuous glucose monitoring to personalize taper and safeguard against hypoglycemia.

• Chiropractic role:

• • Address altered gait mechanics and compensatory pain (low back, hip, knee), restore joint function, reduce soft-tissue tension, and modulate autonomic state to support blood pressure and inflammation control.

• Six-month outcomes:

• • Titrated to full semaglutide dose; completely off insulin.
  • Food noise dramatically reduced; portion control achievable ~75% adherence.
  • Alcohol cravings down—reflecting overlapping reward circuits influenced by incretin therapy.
  • PT adherence improved; bike 15 minutes daily; twice-weekly strength training.
  • Achieved a 10.2% total weight reduction despite inherent challenges (historical insulin, diabetes-associated slower loss, low initial activity).

• One-year transformation:

• • 3% total weight loss; fasting insulin fell to 13.1 µU/mL; HOMA-IR to 3.4; HbA1c down to 6.0%.
  • Body fat decreased to 41.1%; skeletal muscle rose to 29.1% (25th percentile); VAT volume markedly reduced; stamina up; claudication pain minimal.

• Why this worked:

• • Cardioprotective incretin therapy replaced insulin’s weight- and inflammation-promoting footprint.
  • Structured PT plus chiropractic enabled movement despite PAD.
  • Protein pacing and resistance training rebuilt metabolic “engine” (skeletal muscle).
  • CGM empowered precise, safe deprescribing and patient engagement.

Case Narrative: Dolores’s Sarcopenic Obesity, Knee Osteoarthritis, and Navigating Weight Bias

Dolores, 72, sought bilateral knee replacements but faced a strict BMI cutoff (<40). She had severe knee osteoarthritis, insomnia managed with trazodone, hyperlipidemia on rosuvastatin, and profound sarcopenic obesity: BMI 41.5, body fat 56.8%, skeletal muscle 15.1% (2nd percentile), VAT 2.3 L, waist circumference 43.1 inches. She swam 20 minutes three times weekly but feared physical therapy and judgment—reflecting pervasive weight bias I actively counter.

• Immediate and broader goals:

• • Initial 3.9% weight loss to reach surgical eligibility and prepare the body for recovery.
  • Long-term: improve mobility, increase skeletal muscle, reduce VAT, prevent cardiometabolic drift.

• Nutrition strategy:

• • Elevate protein to 90–100 g/day via eggs, fish, cottage cheese, Greek yogurt, hard cheeses, and protein shakes; pace every 3–4 hours to stimulate muscle protein synthesis.
  • Reduce sweets and refined starches; maintain fiber-rich produce.

• Activity and rehabilitation:

• • Continue swimming; start PT with a compassionate, obesity-informed therapist; use a stationary bike as a substitute for painful walking; progressive strength training.

• Pharmacotherapy pathway:

• • Start naltrexone/bupropion for cravings and appetite; pause naltrexone perioperatively to allow opioid analgesia and maintain bupropion; post-op, transition to semaglutide to sustain satiety without analgesic interference.

• Advocacy and bias reduction:

• • Validate her prior negative experiences; coach proactive communication with orthopedics; speak directly with surgeons to challenge rigid BMI gatekeeping and present the catch-22 (pain blocks activity needed for weight loss); emphasize patient-centered risk/benefit framing.

• One-year results:

• • 7% weight loss; fasting insulin normalized; body fat down to 49.8%; skeletal muscle up to the 10th percentile; VAT and waist reduced.
  • First knee successfully replaced without complications; mobility improved; second knee scheduled; semaglutide titrated to 1.7 mg.
  • Travel goals back on the horizon; confidence restored.

• Why this worked:

• • High-protein pacing plus strength training reversed sarcopenia trends.
  • Appropriate medication choices timed around surgery and analgesic needs preserved progress.
  • Chiropractic care bridged pain to functional PT engagement by improving mechanics and lowering neurologic hypervigilance.
  • Active advocacy dismantled barriers rooted in systemic weight bias.

Transform Your Body!- Video

The Role of Integrative Chiropractic Care in Metabolic Health

Chiropractic care is often misunderstood as purely musculoskeletal. In integrative obesity medicine and metabolic care, chiropractic contributes meaningfully by improving nervous system regulation and biomechanics, enabling sustainable movement, and mitigating stress physiology.

• How chiropractic complements metabolic care:

• • Pain relief and mobility: targeted joint adjustments and soft-tissue therapies reduce pain and stiffness, fostering confidence and adherence to activity prescriptions.
  • Autonomic balance: adjustments stimulate mechanoreceptors and modulate sympathetic-parasympathetic tone, aiding blood pressure regulation, sleep quality, and perceived stress.
  • Functional neurology: cervical/thoracic alignment and mobility influence brainstem/autonomic interfaces; optimized posture and proprioception reduce fatigue and cognitive strain in perimenopause and chronic stress states.
  • Movement economy: better biomechanics reduce energy cost of activity, allowing patients to reach protein- and exercise-based muscle-preservation goals with less discomfort.

This integrative chiropractic lens aligns with functional medicine’s focus on root causes and systems biology, while our partnership with internal medicine ensures safety and appropriate medical escalation.

Nutrition Anchors: Protein Pacing, Glycemic Stability, and Inflammation Reduction

To preserve muscle and support satiety on incretin therapies, we emphasize protein pacing: distributing 25–30 grams of protein per meal, with additional protein every 3–4 hours when needed. For older adults and individuals with anabolic resistance, total daily targets often range from 1.2 to 1.6 g/kg of ideal body weight, adjusted for comorbidities and renal function.

• Why protein pacing matters:

• • Stimulates muscle protein synthesis repeatedly throughout the day, countering sarcopenia and supporting resting metabolic rate.
  • Enhances satiety signals and reduces grazing behaviors, especially when combined with fiber-rich plant foods.
  • Supports glucose disposal in skeletal muscle, improving insulin sensitivity.

• Practical strategies:

• • Lean animal proteins, dairy proteins, and high-leucine options such as whey-based shakes.
  • Pair proteins with non-starchy vegetables, healthy fats, and low-glycemic fruits to balance micronutrients and fiber.
  • Use ready-to-drink shakes or smoothies for patients experiencing appetite blunting on GLP-1/GIP therapies.

Dietitian-guided plans personalize macronutrient ratios, timing, and recipes to fit culture, schedule, and preferences, anchored in insulin resistance physiology.

Movement and Rehabilitation: Resistance Training as a Metabolic Prescription

Resistance training is essential in modern obesity medicine. It is not optional if the goal is long-term weight stability and cardiometabolic protection.

• What we prioritize:

• • Twice-weekly strength sessions progressing by load or repetitions, tailored to pain and mobility constraints.
  • Aerobic activity scaled from current capacity: walking, stationary bike, swimming, or low-impact classes.
  • Non-exercise activity thermogenesis (NEAT): frequent short walks, standing breaks, stairs, and posture work.

• Why this works biologically:

• • Skeletal muscle is the primary postprandial glucose sink, improving insulin sensitivity.
  • Preserving lean mass prevents resting metabolic rate decline that otherwise fuels weight regain.
  • Strength increases functional independence, lowers fall risk, and reduces chronic pain via improved mechanics.

Chiropractic care reduces barriers to movement by easing joint restrictions and neuromuscular tension, while PT provides supervised progression and home programs.

Sleep and Stress: OSA, Cortisol Rhythms, and Clinical Strategies

OSA drives hypertension, insulin resistance, daytime fatigue, and nocturnal sympathetic activation. Confirming OSA and initiating CPAP can transform energy, appetite control, and blood pressure—often unlocking stalled progress.

• Stress physiology:

• • Chronic stress elevates cortisol and adrenaline, amplifying VAT accumulation and cravings; poor sleep further dysregulates ghrelin and leptin.
  • Short, guided meditations, breath work, and time-structured micro-practices reduce sympathetic load and improve adherence.

• My clinical approach:

• • Identify barriers (“meditation feels silly”) and create pragmatic workarounds (3-minute car sessions).
  • Leverage chiropractic autonomic effects and sleep hygiene coaching.
  • Collaborate with behavioral health to address grief, anxiety, and cognitive distortions.

The combination of sleep optimization and stress reduction recalibrates appetite physiology, enabling nutrition and pharmacotherapy to perform optimally.

Medication Strategy: Incretin-Based Therapies and Combination Approaches

Modern anti-obesity medications address biology directly. GLP-1 receptor agonists (e.g., semaglutide) and dual GIP/GLP-1 agonists (e.g., tirzepatide) reduce food noise, improve satiety, slow gastric emptying, enhance glucose-dependent insulin secretion, and lower cardiovascular events in high-risk populations.

• Clinical logic:

• • Start low and titrate to minimize GI side effects; educate patients on meal size and hydration.
  • Monitor body composition to protect lean mass; mandate resistance training and protein pacing.
  • Individualize maintenance dosing—use the lowest effective dose for appetite control and stability.

• Combination therapy considerations:

• • If physiological “fight back” emerges (rising hunger, plateaus), consider adding a different mechanism (e.g., naltrexone/bupropion or phentermine/topiramate), not another GLP-1.
  • Align choices with comorbidities, mental health, alcohol use patterns, and perioperative needs.

• Deprescribing insulin:

• • For patients like Amit, replacing exogenous insulin burden with GLP-1/GIP strategies plus CGM improves weight and inflammation while maintaining glycemic stability.
  • Safety first: real-time glucose data, collaborative titration, and robust patient education.

All pharmacologic decisions occur under Dr. Cardenas’s medical direction, with risk-benefit clarity and ongoing monitoring.

Men’s Health Focus: Hypogonadism, Fertility, NAFLD/NASH, Sleep Apnea

Men’s obesity health spans hormonal, hepatic, vascular, and sleep domains:

• Hypogonadism:

• • Adipose-derived aromatase lowers testosterone; low T impairs mood, muscle, and fertility.
  • Fat loss and sleep improvement support endogenous testosterone; when indicated, endocrine evaluation and therapy align with fertility goals.

• Fertility:

• • Improved metabolic health, reduced VAT, and normalized sleep can restore sperm parameters and sexual function.

• NAFLD/MASLD:

• • Weight loss of 7–10% can improve steatosis and lower liver enzymes; incretin therapies and Mediterranean-style nutrition help reverse hepatic fat.

• Sleep apnea:

• • CPAP enhances energy, appetite control, blood pressure, and testosterone rhythms.

Integrative chiropractic care adds autonomic balance and pain relief, enabling compliant movement and metabolic resilience.

Women’s Health Focus: PCOS, Perimenopause, MHT, and Cardiometabolic Risk

Women’s metabolic health must address life-stage physiology:

• PCOS:

• • Insulin resistance drives hyperandrogenism and ovulatory dysfunction; weight reduction and insulin sensitivity improvements are cornerstone therapies.
  • GLP-1/GIP agents, metformin in select contexts, and nutrition/lifestyle changes can restore cycles and reduce cardiometabolic risk.

• Perimenopause and MHT:

• • When appropriate, transdermal estradiol with oral progesterone can stabilize vasomotor symptoms, sleep, mood, and cognition while supporting bone and vascular health.
  • Weight distribution shifts toward VAT; dual focus on satiety medication plus resistance training preserves lean mass.

• Cardiometabolic vigilance:

• • Waist circumference, lipids, blood pressure, and A1c tracking identify risk early; integrated care targets reversible drivers.

Chiropractic care reduces musculoskeletal pain and enhances neurologic tone, promoting consistent activity and better quality of life.

Addressing Weight Bias and Surgical Gatekeeping

Strict BMI cutoffs for procedures like total knee replacement can be harmful and non-patient-centered. Our advocacy aims to:

• Reframe surgical readiness using body composition, functional capacity, and metabolic stability—not a single BMI number.
• Highlight catch-22 dynamics: pain prevents activity necessary for weight loss.
• Document progress in nutrition, medication, and PT; communicate collaboratively with surgical teams.
• Empower patients with scripts and confidence; follow up to ensure continuity.

Reducing bias improves adherence, outcomes, and the therapeutic alliance.

Practical Monitoring, Safety, and Shared Decision-Making

Safety is the bedrock of our model:

• Monitoring:

• • Regular vitals, labs (including HbA1c, fasting insulin/glucose, lipids, liver enzymes), and body composition.
  • Sleep adherence and device data in OSA.
  • Functional strength assessments (e.g., grip strength, sit-to-stand).

• Red flags and escalation:

• • GI escalation on incretin therapy (e.g., severe pain); hydration vigilance; gallstone and pancreatitis warning signs.
  • Perioperative medication adjustments (e.g., naltrexone-bupropion timing).
  • Blood pressure and mood monitoring with med changes.

• Shared decision-making:

• • Clear explanations of rationale and tradeoffs.
  • Goal re-centering around life outcomes: heart health, fertility, mobility, vitality.

Putting It All Together: A Cohesive, Patient-Centered Pathway

From George’s fertility success to Lynn’s perimenopausal restoration, from Amit’s insulin deprescribing triumph to Dolores’s surgical pathway and mobility redemption, the common denominator is personalized, layered, integrative care. Our partnership—Dr. Cardenas ensuring medical rigor and safety; my chiropractic and functional medicine leadership optimizing structure and systems—offers a model for modern obesity and metabolic healthcare that is ethical, empathetic, and effective.

We do not chase numbers for their own sake. We build lives: quieter food noise, stronger muscles, freer movement, clearer cognition, calmer sleep, and safer hearts.

References

• Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., Trillot, N., Barrellier, M. T., Wahl, D., Emmerich, J., Scarabin, P. Y., & Estrogen and Thromboembolism Risk (ESTHER) Study Group. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation, 115(7), 840–845. https://doi.org/10.1161/CIRCULATIONAHA.106.642280
• Ettinger, B., Friedman, G. D., Bush, T., & Quesenberry, C. P., Jr. (1994). Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstetrics and Gynecology, 87(1), 6–12. https://doi.org/10.1016/0029-7844(95)00353-x
• Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
• Gadde, K. M., Martin, C. K., Berthoud, H. R., & V. S. (2018). Bupropion/naltrexone for the treatment of obesity: A review of the clinical evidence. International Journal of Obesity, 42(2), 191–204. https://doi.org/10.1038/ijo.2017.185
• Kelly, D. M., & Jones, T. H. (2013). Testosterone and obesity. Obesity Reviews, 14(2), 91–105. https://doi.org/10.1111/j.1467-789X.2012.01050.x
• Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, E. A., Story, U., Tarp-Johansen, M. J., Wolsk, E., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
• Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., Wactawski-Wende, J., Jackson, R. D., Limacher, M., Gass, M. L., Ockene, J. K., Larson, J. C., Phillips, L. S., & Wallace, R. B. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353–1368. https://doi.org/10.1001/jama.2013.278040
• Marlatt, K. L., & Ravussin, E. (2017). The role of GLP-1 in the regulation of appetite and energy expenditure. Frontiers in Endocrinology, 8, 331. https://doi.org/10.3389/fendo.2017.00331
• Paddon-Jones, D., & Rasmussen, B. B. (2009). Dietary protein recommendations and the prevention of sarcopenia. Current Opinion in Clinical Nutrition and Metabolic Care, 12(1), 86–90. https://doi.org/10.1097/MCO.0b013e3283169ea9
• Papatriantafyllou, E., Efthymiou, V., Zoulekas, P., Zacharof, A., & Kapsoritakis, A. N. (2022). Sleep deprivation: Effects on the human body. Cureus, 14(2), e22401. https://doi.org/10.7759/cureus.22401
• Schoenfeld, B. J., & Aragon, A. A. (2018). How much protein can the body use in a single meal for muscle-building? Implications for daily protein distribution. Journal of the International Society of Sports Nutrition, 15, 10. https://doi.org/10.1186/s12970-018-0215-1
• Stenholm, S., Harris, T. B., Rantanen, T., Visser, M., Kritchevsky, S. B., & Ferrucci, L. (2008). Sarcopenic obesity: Definition, cause and consequences. Current Opinion in Clinical Nutrition and Metabolic Care, 11(6), 693–700. https://doi.org/10.1097/MCO.0b013e328312c37d
• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
• American College of Obstetricians and Gynecologists. (2022). Hormone therapy for perimenopausal and postmenopausal women. ACOG Clinical Practice Guideline No. 8. https://www.acog.org
• Bluher, M. (2019). Obesity: Global epidemiology and pathogenesis. Nature Reviews Endocrinology, 15(5), 288–298. https://doi.org/10.1038/s41574-019-0176-8
• Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., & Look AHEAD Research Group. (2011). Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care, 34(7), 1481–1486. https://doi.org/10.2337/dc10-2415
• Afolabi, A. O., Alagbe, O. A., & Oladipupo, I. (2023). HOMA-IR and its correlation with metabolic syndrome and its components in a Nigerian population. Heliyon, 9(1), e12816. https://doi.org/10.1016/j.heliyon.2023.e12816
• Kuyper, E., & Vissers, D. (2017). The effect of physical activity on functional performance in perimenopausal and postmenopausal women: A systematic review. Maturitas, 101, 47–59. https://doi.org/10.1016/j.maturitas.2017.04.008
• Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015). Pharmacological management of obesity: An endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(2), 342–362. https://doi.org/10.1210/jc.2014-3415
• Bray, G. A., Heisel, W. E., Afshin, A., Jensen, M. D., Ryan, D. H., & Wolfe, B. M. (2018). The science of obesity management: An endocrine society scientific statement. Endocrine Reviews, 39(2), 79–132. https://doi.org/10.1210/er.2017-00253
• Schwartz, M. W., Seeley, R. J., Zeltser, L. M., Drewnowski, A., Ravussin, E., & Redman, L. M. (2017). Obesity pathogenesis: An endocrine society scientific statement. Endocrine Reviews, 38(4), 267–296. https://doi.org/10.1210/er.2017-00111
• Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., … & Loria, C. M. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Journal of the American College of Cardiology, 63(25 Part B), 2985–3023. https://doi.org/10.1016/j.jacc.2013.11.004
• Puhl, R. M., & Heuer, C. A. (2010). Obesity stigma: Important considerations for public health. American Journal of Public Health, 100(6), 1019–1028. https://doi.org/10.2105/AJPH.2009.159491

SEO Tags: integrative chiropractic care, functional medicine, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, El Paso TX, insulin resistance, HOMA-IR, metabolic syndrome, obesity treatment, men’s health, male infertility, low testosterone, stress management, bupropion-naltrexone, semaglutide, GLP-1 agonist, tirzepatide, dual incretin therapy, perimenopause symptoms, menopausal hormone therapy, MHT, brain fog, visceral fat, weight loss journey, patient-centered care, multidisciplinary clinic, sleep apnea, CPAP, lifestyle medicine, nutritional counseling, cardiovascular health, prediabetes reversal, sarcopenic obesity, protein pacing, deprescribing insulin, body composition, NAFLD, MASLD, PAD, orthopedic surgery BMI cutoff, weight bias in healthcare, autonomic nervous system, biomechanics, rehabilitation, personal injury care, dralexjimenez.com, LinkedIn Dr. Jimenez